nature.com web signal

npj commentary rejects AI as panacea for women's health gap

TL;DR

  • A commentary in npj Women's Health argues that 'systemic harms can arise when AI is uncritically embraced as a revolution for women's health.'
  • The authors flag three linked concerns: impoverished understandings of gender and sex, uncritical AI integration amid promotion, and resulting health detriments.
  • The paper is written by researchers at Radboud, MIT, Edinburgh, Swarthmore, UC Berkeley and Lausanne, and funded by the Dutch Research Council.

A group of researchers has published a commentary in npj Women's Health pushing back on the growing framing of AI as a fix for the gaps in women's healthcare. Their central line is blunt: 'systemic harms can arise when AI is uncritically embraced as a revolution for women's health.'

The authors identify three interconnected concerns. The first is what they call impoverished understandings of gender and sex. The second is that those same thin conceptualizations get fed into AI systems amid what the paper describes as promotional enthusiasm. The third is that the resulting tools risk producing health detriments rather than benefits for the patients they are pitched as helping. The piece is a position argument, and the authors urge clinicians and advocates to 'critically examine what AI can and cannot contribute to women's health.'

What makes this more than another generic complaint about algorithmic bias is where it is coming from. The preprint on Zenodo lists authors from Radboud University, MIT, the University of Edinburgh, Swarthmore College, UC Berkeley and the University of Lausanne, with funding from the Dutch Research Council. A lot of AI-for-women's-health pitches lean on the argument that women have historically been under-represented in medical research and that AI can help close the gap. This commentary is arguing that the gap does not close by itself just because a model is trained on the data that already exists.

The honest caveat is that what is public here is a commentary and the preprint description, not a systematic review of specific products or clinical outcomes; the paper does not name individual companies or ship a fix. What it does give buyers of these tools is a checklist to press vendors on before deployment: how sex and gender are defined in the training data, what claims are being made versus what has been validated, and who bears the downside if a model performs worse for the group it was ostensibly built for.

Shared on Bluesky by 2 AI experts